Ascendis Pharma A/S (ASND) vs BridgeBio Pharma (BBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 22.6% versus a gain of 8.8%. Over five years, ASND leads with a +42.8% price change compared with +38.6% for BBIO. Ascendis Pharma A/S is the larger company by market cap ($15.03 billion vs $13.00 billion), about 1.2 times the size.
On valuation, Ascendis Pharma A/S trades at a lower forward P/E (21.1x vs 2420.8x for BridgeBio Pharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | BBIO |
|---|---|---|
| Share price | $228.41 | $66.50 |
| Market cap | $15.03B | $13.00B |
| 1-day change | +1.04% | -0.69% |
| YTD return | +7.11% | -13.06% |
| 1-year return | +8.84% | +22.65% |
| 5-year return | +42.77% | +38.60% |
| P/E ratio (TTM) | 17.50 | — |
| Forward P/E | 21.11 | — |
| EPS (TTM) | $13.05 | $-3.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $502.08M |
| Revenue growth (YoY) | — | +126.26% |
| Net income (latest FY) | — | $-732.94M |
| Gross margin | — | 95.82% |
| Operating margin | — | -104.25% |
| Net margin | — | -145.98% |
| 52-week high | $282.15 | $93.42 |
| 52-week low | $186.05 | $52.75 |
| Distance from 52-week high | -19.05% | -28.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +33.90% | +63.98% |
| Average volume | 656.21K | 2.76M |
| Shares outstanding | 65.80M | 195.49M |
| Employees | 1,189 | 999 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed ASND by 13.8 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
ASND vs BBIO FAQ
Which is bigger, Ascendis Pharma A/S or BridgeBio Pharma?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $15.03B compared with $13.00B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, ASND or BBIO?
BBIO returned +22.65% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and BridgeBio Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.